A 31-year-old female receives a kidney transplant for autosomal dominant polycystic kidney disease (ADPKD). Three weeks later, the patient experiences acute, T-cell mediated rejection of the allograft and is given sirolimus. Which of the following are side effects of this medication?
ANephrotoxicity, hypertension
BHyperlipidemia, thrombocytopenia
CNephrotoxicity, gingival hyperplasia
DPancreatitis
ECytokine release syndrome, hypersensitivity reaction
A patient with HCC and a long history of alcohol dependence and chronic hepatitis C has been using the mTOR inhibitor sirolimus 100 mg for cancer treatment. Her cancer has shown a partial response. She also has a history of hypertension and poorly controlled type 2 diabetes mellitus complicated by diabetic retinopathy. Current medications include enalapril and insulin. She asks her oncologist and hepatologist if she could try everolimus for its purported survival benefit in treating HCC. Based on clinical considerations, which of the following statements is most accurate?
AThe patient should start everolimus 50 mg because of the survival benefit relative to sirolimus 100 mg
BThe patient is not a good candidate for everolimus due to her history of hypertension
CThe patient should start everolimus 100 mg because of the survival benefit relative to sirolimus 100 mg
DThe patient should start everolimus 50 mg because of her history of alcohol use disorder and hepatitis C
EThe patient is not a good candidate for everolimus due to her history of diabetes
An epidemiologist is evaluating the efficacy of Noxbinle in preventing HCC deaths at the population level. A clinical trial shows that over 5 years, the mortality rate from HCC was 25% in the control group and 15% in patients treated with Noxbinle 100 mg daily. Based on this data, how many patients need to be treated with Noxbinle 100 mg to prevent, on average, one death from HCC?
A20
B73
C10
D50
E100
+ 7 more in the PDF
Browse all chapters